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Abstract
Background: Selection of the right warfarin dose at the outset of treatment is not straightforward, and current
evidence is lacking to determine the optimal strategy for initiation of therapy.
Methods: We included randomized controlled trials in patients commencing anticoagulation with warfarin,
comparing different loading dose or different regimens.
We searched Medline, EMBASE, the Cochrane Library and the NHS Health Economics Database up to June 2009.
Primary outcomes were time to stable INR and adverse events. We summarised results as proportion of INRs in
range from date of initiation and compared dichotomous outcomes using relative risks (RR) and calculated 95%
confidence intervals (CIs).
Results: We included 11 studies of 1,340 patients newly initiated on warfarin. In two studies that used single INR
measures, a loading dose of 10 mg compared to 5 mg led to more patients in range on day five. However, in two
studies which measured two consecutive INRs, a loading dose of 10 mg compared to 5 mg did not lead to more
patients in range on day five (RR = 0.86, 95% CI, 0.62 to 1.19, p = 0.37). Patients receiving a 2.5 mg initiation does
took longer to achieve the therapeutic range, whilst those receiving a calculated initiation dose achieved target
range 0.8 days quicker (4.2 days vs. 5 days, p = 0.007). More elderly patients receiving an age adjusted dose
achieved a stable INR compared to the Fennerty protocol (48% vs. 22% p = 0.02) and significantly fewer patients
on the age adjusted regimens had high out-of-range INRs. Two studies report no significant differences between
genotype guided and 5 mg or 10 mg initiation doses and in the one significant genotype study the control group
INRs were significantly lower than expected.
Conclusion: Our review findings suggest there is still considerable uncertainty between a 10 mg and a 5 mg
loading dose for initiation of warfarin. In the elderly, lower initiation doses or age adjusted doses are more
appropriate, leading to less higher INRs. Currently there is insufficient evidence to warrant genotype guided
initiation, and adequately powered trials to detect effects on adverse events are currently warranted.
Background
Oral anticoagulants are effective for the prevention and
treatment of thromboembolic events [1-4] and are used
in many conditions including deep vein thromboses
(DVT), pulmonary emboli (PE), mitral and aortic valve
replacements (MVR/AVR) and atrial fibrillation (AF),
together with occasional use in patients with heart fail-
ure and those with peripheral and cerebral vascular dis-
ease. The use of oral anticoagulants such as warfarin
has increased substantially over the last 10 years, parti-
cularly within the context of an ageing population [5,6].
Although warfarin is an effective antithrombotic agent
the therapeutic range is narrow due to the balance
between reducing thrombotic events without increasing
the risk of bleeding. To monitor therapy, an Interna-
tional Normalized Ratio (INR) between 2.0 and 3.0 is
generally accepted for these conditions with the excep-
tion of valve replacements where a higher INR between
2.5 and 3.5 is usually recommended [7,8].
Given the wide variation on dose response to warfarin,
careful monitoring is required especially in the initiation
phase of treatment. Different methods of initiating war-
farin aim to establish the therapeutic window efficiently
without causing adverse effects. Some conditions (i.e.
deep vein thrombosis) require the establishment of
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reduce concomitant treatments such as heparin, and
reduce costs. In other conditions, such as outpatient
diagnosis of atrial fibrillation, the time to establish the
therapeutic range is not as crucial.
Initial doses of warfarin include 10 mg [9], 5 mg [10],
2.5 mg [11], and, in the elderly, lower doses such as 1
mg [12]. In addition, initiation dosing can occur by
using protocols such as Fennerty’s, which relies on con-
secutive daily INRs over the first four days to predict
the next day’s warfarin dose [13]. There has also been
considerable interest in genotype guided warfarin initia-
tion [14]. Warfarin is a racemic mixture of R and S
enantiomers; the more potent S-warfarin is metabolised
i nt h el i v e rb yc y t o c h r o m eP 4 5 02 C 9 .T h ew i l d - t y p e
allele is labelled CYP2C9*1, two other alleles, CYP2C9*2
and CYP2C9*3, result in warfarin being metabolised
more slowly, and carriers of these alleles potentially
have a greater risk of bleeding during initiation of war-
farin and subsequently require lower doses [15].
Balancing the need for effective anticoagulation, with
reduced time to therapeutic INR and without concomi-
tant increases in adverse events is important, not only
for patients, but for heath care systems in terms of eco-
nomic costs [16]. Selection of the right warfarin dose at
the outset is not straightforward, and current evidence
is lacking to determine the optimal strategy; therefore
we set out to systematically review the literature on the
most effective methods for initiating warfarin.
Methods
We included randomized controlled trials in patients
commencing anticoagulation with warfarin, comparing
different loading dose or different regimens at the initia-
tion of therapy. Included trials had one or more of the
following outcomes: time to stable INR range, doses
withheld, supra-therapeutic INRs and/or, adverse events.
We searched the following databases: Medline (1966 -
2009), EMBASE, the Cochrane Library including the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), Database of Reviews of Effectiveness (DARE)
and the NHS Health Economics Database up to June
2009 using a maximally sensitive strategy (Dickersin et
al 2002). Search terms included Warfarin/ad (Adminis-
tration & Dosage), Anticoagulants, Warfarin, (anticoa-
gula* or warfarin or coumadin).tw. combined with the
following search terms: Drug Administration Schedule,
Dose-Response Relationship, Drug, ((Fennerty* or age
adjusted or empirical or fixed) adj5 (regime* or method*
or protocol* or algorithm*)).tw., ((dosing or dose* or
dosage*) adj5 (empirical or regime* or method* or pro-
tocol* or algorithm* or nomogram*)).tw. ((initial or
initiation or induction or loading) adj3 (dose* or dosage*
or dosing)).tw.
Two researchers independently reviewed the title and
abstracts of electronic searches, obtaining full-text arti-
cles to assess inclusion where necessary. We performed
citation searches and reviewed references of all full text
papers retrieved. Disagreements were resolved by discus-
sion with a third author. Where data was insufficiently
reported in the published paper we wrote to the original
authors for clarification and further information.
Data extraction
Two authors (ST and CB) independently extracted data
and assessed quality with an extraction template; dis-
agreements were documented and resolved by discus-
sion with a third author (CH). Primary outcomes were
time to stable INR; supra-therapeutic INR, sub-thera-
peutic INRs, Vitamin K given, and the following serious
adverse events: bleeding, thrombotic events and death.
Secondary outcomes sought were economic costs, hospi-
tal stay, length of concomitant therapy and frequency of
INR tests. To define adverse events we used the defini-
tions reported in the primary studies (see Table 1).
We assessed methodological quality of the included
studies for the following components: allocation con-
cealment, randomisation, blinding of outcome assessors,
and follow up. Where data was presented only in gra-
phical form we extracted from the figures using the
Grab It XP Microsoft excel. http://www.datatrendsoft-
ware.com.
Data synthesis and analysis
We summarised results as proportion of INRs in range
from date of initiation. We reported the proportion of
I N R si nr a n g ea td a yo n et h r o u g hd a ye i g h tw h e r e
applicable, as well as the mean time to in range, in days,
with standard deviations. For dichotomous outcomes we
compared different regimens using relative risks (RR)
and calculated 95% confidence intervals (CIs). For con-
tinuous variables we compared weighted mean differ-
ence (WMD) with 95% CIs. Where we pooled data we
used the i-squared statistic to measure statistical hetero-
geneity for each outcome. Where no heterogeneity was
present, we used a fixed-effect meta-analysis and where
substantial heterogeneity (i-squared above 50%) was
detected, we looked for the direction of effect and used
a random effects analysis. No previous protocols have
been published for this current review. Insufficient data
to pool outcomes by type of loading dose prevented
assessment of publication bias and selective reporting of
studies.
Results
We identified 147 potentially relevant records from 687
published papers, of these two reviewers identified 129
as not relevant or not randomized (Figure 1). On
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Study Recruitment
Setting
Eligible
Population
(average age)
Inclusion/Exclusion criteria Protocol Outcomes
5 mg vs. 10 mg
Harrison
(1997)
Canada
Inpatients &
outpatients
51 patients *
(64 yrs)
%not available
INR target 2.0-3.0 1) Time to INR in range,
2) INR >3.0,
3) Time to reduction in factors II,
X and protein C
Crowther
(1999)
Canada
Thromboembolism
unit
53 patients *
(65 yrs)
47% male
INR target 2.0-3.0. Exclusions: contraindication to
warfarin or geographically inaccessible
1) Proportion with INR in range
for 2 consecutive days on days 3
& 4, or 4 & 5 and INR not >3.0
Kovacs
(2003)
Canada
Outpatient clinics 201 patients with
DVT or PE
(55 yrs)
56% male
Exclusions: baseline INR >1.4, thrombocytopenia, <18
yrs, hospitalised, oat in previous 2 wks, high risk of
bleeding
Primary Outcome:
1) Time to INR >1.9.
Secondary Outcomes:
2) INR in-range by day 5
3) VTE by day 90
4) Major bleeding by 28 days
5) INR >5.0
6) Number of INRs in 28 days
7) Death by 90 dys
Quiroz
(2006)
USA
Inpatients 50 patients with
DVT or PE
(50 yrs)
54% male
Exclusions: <18 yrs, not available for clinic f/up,
warfarin or heparin >36 hrs, creatinine clearances of
<30 ml/min, life expectancy <3 mths, high risk of
bleeding
Primary Outcome:
1) Time to INR >1.9 on 2 consec.
days.
Secondary Outcomes:
2) Recurrent VTE at 14 days
3) Death at 14 days
4) Major bleeding at 14 days
5) INR >5 at 14 days
5 mg vs. 2.5 mg
Ageno
(2001)
Canada
&Italy
Inpatients 232 patients with
heart valve
replacement
(64 yrs)
56% male
INR target 2.0 (range 1.5-2.6). Exclusions: baseline INR
>1.3
Primary Outcome:
1) % INR >2.6
Secondary Outcomes:
2) Time to INR in range
3) % out of range
4) Vit. K/bleeding/thromboembolic
events
5) Dose adjustments/mean daily
dose
5 mg vs. calculated dose
Shine
(2003)
USA
Inpatients 90 patients with
AF, DVT, PE or
other
(61 yrs)
58% male
INR target 2.0-3.0 & INR = 1.4. Exclusion; warfarin in
previous 3 months
1) Time to INR in range
2) Hours in hospital
3) Number with INR 2.0-3.0
4) Factor II protein activity
5) Clinical complications
6) INR ever >4.0 or a rise of 2.0
over 2 days to >3.0
Age adjusted
Roberts
(1999)
Australia
Inpatients 65 patients with
AF, DVT, PE &
other
(74 yrs)
70% male
INR target 2.0-3.0. Exclusions: prolonged diarrhoea,
nasogastric/enteral feeds, commencing amiodarone,
advanced malignancy, Vitamin K in previous 2 wks
Primary Outcome
1) Time to INR in range on 2
consecutive days or if previous
day within 0.5
Secondary Outcomes
2) No. with INR >4.0 in first week
3) Dose withheld in wk1
4) No. of days with heparin
Gedge
(2000)
UK
Inpatients 127 patients with -
AF, DVT, PE &
other
(75 yrs)
50% male
INR target 2.0-3.0. Elderly patients with standard
indications.
1) Time to INR >2.0
2) Days INR in range
3) Number with INR >4.5
4) Dose prediction day 4
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Page 3 of 12540 duplicate and not 
relevant records excluded 
687 published papers identified  
129 records excluded 
because non RCTs 
147 potentially relevant records 
screened by 2 reviewers 
18 retrieved for more detailed 
evaluation 
7 excluded because non 
RCTs or duplicates 
11 appropriate RCTs included in 
the systematic review 
Figure 1 Flowchart of results.
Table 1: Study Characteristics (Continued)
Genotyping
Hillman
(2005)
USA
Inpatient &
Outpatients
38 with DVT, PE,
AF, other,
postoperative
orthopaedic
(70 yrs)
45% male
Exclusions: antiphospholipid antibodies,
contraindication for warfarin, previous warfarin, liver
disease, renal disease, non-Caucasian, <40 yrs.
Primary Outcome:
1) Feasibility of dosing model
Secondary Outcomes:
2) % time INR in-range
3) % pts with INR >4
Anderson
(2007)
USA
Inpatient &
Outpatients
201 with DVT, PE,
AF, other,
preoperative
orthopaedic
(61 yrs)
53% male
INR target 2.0-3.0. Exclusions: <18 yrs, women,
pregnant, lactating or child-bearing potential,
rifampin within 3 wks, co-morbidities precluding
standard dosing (advanced physiological age,
hepatic or renal insufficiency/creatine of <25 mg/dl,
terminal illness)
Primary Outcome
1) % INR out of range/patient
Secondary Outcomes:
2) time to INR >3.2 or VitK
3) %pts in range days 5 &8
4) Number of INR measures &
dose adjustments
5) %pts with SAEs - INR ≥4, VitK,
major bleeding, thromboembolic
events, stroke, MI & death)
Caraco
(2008)
Israel
Inpatients 232 with DVT, PE,
AF
(58 yrs)
46% male
Exclusions: <18 yrs and baseline INR >1.4 Primary Outcomes:
1) Time to INR >2.0
2) time to stable anticoagulation
(defined as 2 INR in-range 7 days
apart)
Secondary Outcomes:
3) %Time INR in-range
4) Days INR out of range
5) Major bleeding/VTE events
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because they were not randomised trials or were dupli-
cate publications. A total of 11 papers met the inclusion
criteria [9,11,13,17-24].
All patients included in the studies were newly
initiated on warfarin. In ten studies the recruited
patients had target INR in the range of 2.0-3.0
[9,13,17-24], in two studies the inclusion criteria were
patients with DVT or PE only [22,23]. One further
study included patients after heart valve replacement,
target INR of 1.5-2.6 [11]. In total 1,340 patients were
randomized and eligible (range 38 to 232 participants
per study), with 118 (9%) not included in the primary
outcome analysis. Reasons being: withdrawn (n = 17),
dose deviation or INR missed (n = 68), warfarin stopped
or discharged (n = 29) and one each for Vitamin K
administered, coincidental bleeding, died, or catheter-
ized. Patients were recruited from both inpatient and
outpatient clinics in: USA (4 studies), Canada (3), UK
(1), Israel (1), Australia (1) and multinational (1 - Italy
& Canada).
Trials varied in relation to the loading doses compared
and the dose protocols that were used. (Table 1) The
warfarin loading doses compared were: 5 mg versus 10
mg (4 studies) [9,19,22,23]; 5 mg versus 2.5 mg (1) [11];
5 mg versus dose adjusted for clinical factors (1) [24];
10 mg versus dose adjusted for age (2) [13,20]; 5 mg
versus dose adjusted for genotype (2) [18,21] and 10 mg
versus dose adjusted for genotype (1) [17].
Studies used a variety of initiation dosing protocols in
both arms of the trials. (Table 2) In six studies INR was
measured daily up to day five [9,11,18,19,23,24], and in
three studies INR was measured at times pre-specified by
the dosing protocol[17,21,22] Follow-up varied from five
to 90 days. Outcomes measured included: time to INR in
range, percentage time in-range, percentage in-range at
day five, percentage with an INR above range, time to
reach ‘stable’ anticoagulation (as defined by each study),
percentage with an INR >4.0-5.0, proportion of serious
adverse events such as serious bleeding, VTE, death.
Methodological quality was generally poor with only
one study (Kovacs 2003) [22] reporting adequate rando-
mization, allocation concealment, double blinding and
intention to treat analysis. Study assessment was hin-
dered by lack of reporting of these quality components;
however, a number of studies indicate these components
did not take place. (Table 3)
Although there was considerable heterogeneity across
the eleven studies in terms of design quality, loading
dose protocols, patient population, outcome measures,
and length of follow-up (Tables 1,2,3), we grouped them
into four clinically relevant categories: 5 mg versus 10
mg [9,19,22,23]; 5 mg versus other doses [11,24]; age
adjusted [13,20] and genotype loading dose [17,18,21].
Table 2 Dosing regimes
Study Dosing Protocol on Days 1&2 (Reference for nomogram used)
Harrison 1997
ξ 5 mgs on day 1, up-to 5 mgs on day 2 vs. 10 mgs on day 1, up-to 10 mgs on day 2
Crowther 1999
ξ 5 mgs on day 1, up-to 5 mgs on day 2 vs. 10 mgs on day 1, up-to 10 mgs on day 2
Kovacs 2003 5 mgs vs. 10 mgs on days 1&2
δ
Quiroz 2006 5 mgs vs. 10 mgs on days 1&2
5 mg trials
Ageno 2001 5 mg Day 0 (subsequent doses adjusted) vs. 2.5 mg on days 0 through 4 (dose modified if <1.5 or >3.0 on day 3)
Shine 2003 5 mg on day 1, up-to 5 mgs on day 2 vs. Calculated dose on day 1, up-to 100% calculated dose on day 2
Age trials
Roberts 1999 Age adjusted nomogram (6-10 mg) on day 1, 0.5-10 mg on day 2 vs. Fennerty protocol (10 mg on day 1, 0.5 mg-10 mg on day 2)
ψ
Gedge 2000 Age stratified 65-75 years & 75 yrs - 10 mg on day 1, upto 5 mg on day 2 vs. Modified Fennerty protocol, 10 mg day 1 and
up to 10 mgs on day 2
Genotyping trials
Hillman 2005 5 mg on days 1 & 2 vs. Model - genetic nomogram
Anderson 2007 10 mg on days 1 & 2 vs.
Model - 2× predicted maintenance dose on days 1 & 2 followed by predicted dose
Caraco 2008 5 mg on day 1 & up to 5 mg on day 2 vs.
Model - genetic nomogram
ξ Crowther 1997 report: Crowther MA, Harrison L, Hirsh J. Reply: Warfarin: Less May Be Better. Ann Intern Med 1997 August 15;127(4):333.
δ Kovacs MJ, Anderson DA, Wells PS. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment of venous
thromboembolism. Pathophysiol Haemost thromb 2002;321:131-133
ψ Fennerty A, Dolben J, Thomas P et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. British Medical Journal Clinical Research
Ed 1984 April 28;288(6426):1268-70.
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Four studies (355 patients) compared 5 mg versus 10
mg loading doses. (Figure 1) [9,19,22,23] Tables 1 and 2
illustrate the nomograms used for dosing which varied
across the studies, as well as patient characteristics and
inclusion criteria. All four studies reported INR in-range
by day five (Figure 2) but high heterogeneity (I
2 = 83%)
prevented pooling (Figure 3). One possible reason for
this is that studies report the proportion either as single
or two consecutive INR measures. In the two studies
that used single INR measures (Harrison, Kovacs) [9,22]
a loading dose of 10 mg led to more patients in range
on day five although heterogeneity remained high (Fig-
ure 3). Kovacs, also reported the mean time to being in-
range was significantly shorter using a 10 mg than a
5 mg loading dose (5.6 vs. 4.2 days, p < 0.001) [22].
(Table 4)
In contrast, in the two studies that required two con-
secutive INRs at day five (Crowther, Quiroz) [19,23] a
10 mg loading dose did not lead to more patients in-
range on day five (RR = 0.86, 95% CI, 0.62 to 1.19, p =
0.37, I
2 22%). In addition, in the Quiroz study [23] the
authors report the 5 mg group achieved therapeutic
INRs more often during days 6 to 14 (raw data not
available), reporting no difference in median time to two
consecutive INR being in-range (Table 4).
Kovacs [22] and Quiroz [23] reported the proportion
of patients with INR ≥5.0 (Table 4) and found no signif-
icant differences between the two dosing groups. Harri-
son [9] reported administering Vitamin K more
frequently to patients in the 10 mg group; however, the
difference was not significant and it was administered to
patients with INR ≥4.8. Although the number of serious
adverse events was reported by three studies [9,22,23],
there was insufficient power to evaluate the effect of
the loading doses on these and there was considerable
variation in the time frames used - 5 days to 90 days
(Table 1).
5 mg versus other doses
Two studies (322 patients) compared a 5 mg loading
dose with 2.5 mg, (Ageno) [11] and 5 mg with a calcu-
lated dose (Shine) [24]. In the Ageno study in heart-
valve replacement patients (INR target 1.5 to 2.6),
patients receiving 2.5 mg took longer to achieve the
therapeutic range (2.7 vs. 2.0 days; p < 0.0001), but were
less likely to have an INR >2.6 (26% vs. 42;% p < .05)
and had less days with INR >2.6 (average 0.9 vs. 0.45
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Figure 2 Proportion of Patients with a therapeutic INR from day of initiation (5 mg vs. 10 mg).
Table 3 Methodological Quality
Ageno
2001
Anderson
2007
Caraco
2007
Crowther
1999
Gedge
2000
Harrison
1997
Hillman
2005
Kovacs
2003
Quiroz
2006
Roberts
1999
Shine
2003
Randomisation
Method
+ + + + NM + + + + NM +
Concealment of
allocation
NM + - NM NM NM + + NM - +
Double blinding NM + - - NM - - + - - NM
Intention to treat - - - - - - + + + - -
+ Reported in paper
- Paper indicates that did not take place
NM: Not mentioned in paper
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Page 6 of 12days; p = 0.003). There were no serious adverse events
in either group and although Vitamin K was adminis-
tered to more patients in the 2.5 mg group, the differ-
ence was not significant.
Shine compared 5 mg with a calculated dose [24],
which took account of age, weight, serum albumin and
active malignancy. Patients receiving the calculated dose
achieved the target range quicker (4.2 days vs. 5 days,
p = 0.007); but there was no difference in proportion
achieving INR in-range on or before day 6: 77% calcu-
lated dose compared to 63% in the 5 mg dose (RR =
1.22, 95% CI, 0.88 to 1.70, p = 0.24). There were no
differences in serious adverse events or above-range INR
(Table 4).
Age adjusted
Two studies (192 patients) compared loading doses
adjusted for age (Roberts, Gedge) [13,20] with Fennerty’s
protocol [13] or a modified Fennerty protocol [20] in
the standard arm (Table 2).
In the Roberts study, the age adjusted protocol speci-
fied different loading doses for five age groups[13] The
first dose for each of these groups was: age up to 50
years - 10 mg; 51 to 65 years - 9 mg; 66 to 80 years -
All studies 
Risk Ratio
, 95% CI
1.5 2
Favours 10 mg 
1 0.5 0.7
Favours 5mg 
0.77 [0.55, 1.07]
1.20 [0.85, 1.69]
1.78 [1.41, 2.25]
1.08 [0.65, 1.80]
5% CI M-H, Random, 9
Risk Ratio
31
24
97
25
Total In range 
5 mg
27
16
45
13
In range 
10 mg
Total
21
25
104
25
14
20
86
14
Heterogeneity: Tau² = 0.15; Chi² = 18.17, df = 3 (P = 0.0004); I² = 83%
Study or Subgroup
Crowther 1999
Harrison 1997
Kovacs 2003
Quiroz 2006
Single INR measures 
Risk Ratio
, 95% CI
1.5 2
Favours 10 mg 
1 0.5 0.7
Favours 5mg 
1.20 [0.85, 1.69]
1.78 [1.41, 2.25]
5% CI M-H, Random, 9
Risk Ratio
24
97
Total In range 
5 mg
16
45
IN range 
10 mg
Total
25
104
20
86
Heterogeneity: Tau² = 0.06; Chi² = 3.62, df = 1 (P = 0.06); I² = 72%
Study or Subgroup
Harrison 1997
Kovacs 2003
Consecutive INR measures  
Risk Ratio
M-H, Random, 95% CI
1.5 2
Favours 10 mg 
1 0.5 0.7
Favours 5mg 
0.86 [0.62, 1.19]
0.77 [0.55, 1.07]
1.08 [0.65, 1.80]
5% CI M-H, Random, 9
Risk Ratio
100.0%
66.0%
34.0%
Weight
56
31
25
Total In range 
5 mg
27
13
46
I n range 
10 mg
Total
21
25
14
14
Heterogeneity: Tau² = 0.01; Chi² = 1.29, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI)
Study 
Crowther 1999
Quiroz 2006
Figure 3 Proportion of patients with a therapeutic INR at day 5 (10 mg versus 5 mg).
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Page 8 of 127.5 mg; and >80 years - 6 mg. This dose was either
repeated on day two or adjusted according to INR levels.
The doses were further decreased by 33% if the patients
had one or more of: severe congestive failure, severe
chronic obstructive airways disease or amiodarone use.
Table 4 shows that by day five Roberts reported more
patients in the age adjusted group achieved a stable
INR (defined as in-range on 2 consecutive days or
within 0.5) than the Fennerty group (48% vs. 22%
p = 0.02), and this trend continued throughout the
study (Figure 4).
In the Gedge study elderly patients (≥65 yrs) in the
age adjusted arm were given 10 mgs on day one and 5
mgs on day two (or less depending on INR levels) [20].
T h em e a nt i m et oa ni n - r a n g eI N Rw a ss i g n i f i c a n t l y
longer for patients on the age adjusted regimen: age 65
to 75 years (4.6 vs. 3.8 days p = 0.03); age >75 years (4.5
vs. 3.5 days p = 0.003). In both studies significantly
fewer patients on the age adjusted regimens had high
out-of-range INR (Table 4).
Genotyping trials
Three studies (471 patients) compared loading doses
calculated according to patient genotype (genotype
model) with 5 mg or 10 mg loading doses[17,18,21]
Anderson [17] and Caraco [18] reported a greater pro-
portion of patients’ in-range in the genotype group on
day five (Table 4). Caraco also reported that the geno-
type groups spent significantly more time in-range (p <
0.001) but the figure at day five of 15% in range in the 5
mg group was significantly lower than expected at this
dose in comparison to similar arms from the other 5
mg trials. (Figure 5) The other two studies report no
significant differences between genotype guided, and 5
mg or 10 mg initiation doses. No significant differences
were seen for adverse events and no studies were ade-
quately powered to show a difference in major bleeds.
Discussion
Our systematic review is the first comprehensive analy-
sis of randomized trials of different approaches to the
initiation of warfarin. Overall we found a 10 mg loading
dose makes a single therapeutic INR measure in-range
more likely at five days. Yet, when we analysed two
consecutive INR measures at day five the benefits of a
10 mg loading dose were not as apparent. The high het-
erogeneity between the numbers of patients in range in
the 10 mg trials at day five probably reflects that this
measure is highly variable and not the best overall mea-
sure of the quality of INR control. A 5 mg loading dose
compared to 2.5 mg slightly decreased the time to
r a n g e-a b o u th a l fad a y-b u ta tt h ee x p e n s eo fa
greater proportion of overall higher INRs. We found
some evidence that age adjusted nomograms may be of
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Page 9 of 12benefit in the elderly; however, trials were underpow-
ered to detect important rates of adverse events. The
evidence of benefit for genotyping proved disappointing,
as in the one trial which showed a significant benefit,
the quality of INR control for the comparator (5 mg
loading dose) was substantially worse than any other 5
mg study groups in the systematic review. Recent work
from a cohort of 4,043 patients which stated the use of
pharmacogenetics was appropriate for estimating the
initial dose closer to the maintenance dose may have
overestimated the potential usefulness of such an
approach [25].
Our results are not definitive as trials were generally
small; however, they do raise important issues for cur-
rent practice for the initiation of warfarin. The question
as to what is the optimal initiation dose remains unan-
swered by analysis of the current evidence-base. A 5 mg
regimen has been shown to give a more accurate predic-
tion of maintenance dose (correlation co-efficient for
predicted versus actual maintenance dose, r = 0.985)
[12]. Whether this gives rise to a reduction in adverse
events remains unanswered. In the American College of
Chest Physicians Guidelines a 5 mg loading dose is
potentially appropriate in the elderly patient, in patients
with impaired nutrition, liver disease or congestive heart
failure and in patients as risk of bleeding [26].
From our systematic review there is little evidence to
use genotyping, which conflicts with the recent FDA
statement, and the change in labelling for warfarin ther-
apy, which states: “...lower initiation doses should be
considered for patients with certain genetic variations in
CYP2C9” [27]. Our findings are in accordance with a
recent systemic review [28] that showed there are only
three randomized trials of genotyping; which are under-
powered, and with significant heterogeneity between
trials results. In addition, a recent editorial by Ansell
notes “most problematic is that the intervention arm of
each trial is considerably different” [27]. Therefore cur-
rent use of genotyping is not underpinned by the evi-
dence and should be discouraged,
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Figure 4 Proportion of Patients with a therapeutic INR from day of initiation (Age related vs. 10 mg).
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Figure 5 Proportion of Patients with a therapeutic INR from day of initiation (Genotype vs. 10 mg or 5 mg).
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Page 10 of 12During treatment induction with warfarin, elderly
patients are especially at high risk of over-anticoagula-
tion [29]. Based on studies that show, generally, daily
maintenance doses are about 3 to 4 mg in the elderly
[ 3 0 ]t h ee v i d e n c es u g g e s t sa na g ea d j u s t e di n i t i a t i o n
strategy dosage may improve the quality of control.
I ft i m ei sn o tac r u c i a li s s u et h e na ni n i t i a t i o nd o s eo f
2.5 mg is a plausible alternative and the evidence suggests
there is little difference between 2.5 and 5 mg dose.
A number of limitations are worth noting. Firstly,
although our search was comprehensive, the possibility
of missing trials exists. We attempted to overcome this
by citation searching and snowballing of the literature.
Secondly, our conclusions are limited by the quality of
the trials, with only one study scoring high on methodo-
logical quality. Also the results are not significant, as
trials and any pooling of effects are underpowered. A
large multicentre trial is currently warranted which
should address important adverse event rates by being
adequately powered to detect these. Thirdly, often data
was missing from the reported studies, and heterogene-
ity in how primary and secondary outcomes were
reported prevented adequate pooling and firm conclu-
sions to be drawn. This can be rectified by standardized
reporting which would include single and consecutive
measures reported for outcomes at days 3 through to 8,
follow up for adverse events for 30 days after initiation
and proportion of INR measures ≥4.
Conclusions
In conclusion our review shows there is a paucity of
high quality evidence to guide initiation of warfarin.
There is no evidence to suggest a 10 mg loading dose is
currently superior to 5 mg. In the elderly lower initia-
tion doses or age adjusted doses may be more appropri-
ate, leading to less higher INRs. Currently there is
insufficient evidence to warrant genotype guided initia-
tion, and an adequately powered trial to detect effects
on adverse events is currently warranted.
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